- Home
- PIII vs NRXP Comparison
PIII vs NRXP Comparison
Compare PIII & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PIII
- NRXP
- Stock Information
- Founded
- PIII 2015
- NRXP 2015
- Country
- PIII United States
- NRXP United States
- Employees
- PIII N/A
- NRXP N/A
- Industry
- PIII Medical/Nursing Services
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- PIII Health Care
- NRXP Health Care
- Exchange
- PIII Nasdaq
- NRXP Nasdaq
- Market Cap
- PIII 30.8M
- NRXP 32.6M
- IPO Year
- PIII N/A
- NRXP N/A
- Fundamental
- Price
- PIII $6.62
- NRXP $3.27
- Analyst Decision
- PIII Buy
- NRXP Strong Buy
- Analyst Count
- PIII 2
- NRXP 4
- Target Price
- PIII $16.25
- NRXP $28.50
- AVG Volume (30 Days)
- PIII 5.1K
- NRXP 402.2K
- Earning Date
- PIII 05-15-2025
- NRXP 05-15-2025
- Dividend Yield
- PIII N/A
- NRXP N/A
- EPS Growth
- PIII N/A
- NRXP N/A
- EPS
- PIII N/A
- NRXP N/A
- Revenue
- PIII $1,485,192,000.00
- NRXP N/A
- Revenue This Year
- PIII N/A
- NRXP N/A
- Revenue Next Year
- PIII $6.01
- NRXP N/A
- P/E Ratio
- PIII N/A
- NRXP N/A
- Revenue Growth
- PIII 9.79
- NRXP N/A
- 52 Week Low
- PIII $6.47
- NRXP $1.10
- 52 Week High
- PIII $33.73
- NRXP $6.01
- Technical
- Relative Strength Index (RSI)
- PIII 30.04
- NRXP 79.36
- Support Level
- PIII $6.47
- NRXP $2.55
- Resistance Level
- PIII $7.45
- NRXP $2.72
- Average True Range (ATR)
- PIII 0.29
- NRXP 0.25
- MACD
- PIII -0.09
- NRXP 0.05
- Stochastic Oscillator
- PIII 8.26
- NRXP 99.07
About PIII P3 Health Partners Inc.
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.